來源:[1] Syndax Pharmaceuticals:Revumenib PDUFA 審查 mNPM1 AML 並邁向 MSS CRC (https://seekingalpha.com/article/4821782-synd ...)[2] Syndax 公佈 2025 年第二季度財務業績並提供業務更新 (https://vertexaisearch.cloud.google.com/groun ...)[3] Stifel 恢復對 Syndax Pharmaceuticals 股票的覆蓋,評級為買入 - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)